METiS Technologies secures RMB 400 million in Series D financing, co-led by Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund, to enhance its biopharmaceutical innovations.

Aug 05, 2025•14 days ago

Amount Raised

¥400 Million

Round Type

series d

CambridgeTherapeuticsArtificial IntelligenceBiotechnology

Investors

Daxing Industrial Investment FundBeijing Medical And Health Industry Investment Fund

Description

METiS Technologies has successfully completed its RMB 400 million Series D financing round. This funding will accelerate its core strategic initiatives, including automation upgrades, pipeline development, and global partnerships. The round was co-led by the Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund. The new capital aims to advance METiS' position in the biopharmaceutical sector.

Company Information

Company

METiS Pharmaceuticals

Location

Cambridge, Massachusetts, United States

About

METiS Technologies is a pioneering TechBio company unlocking a healthier world through AI-driven nanotechnology. At the intersection of artificial intelligence and nanomaterial science, METiS transforms the delivery and application of active agents across life forms. Founded by MIT-trained scientists, the company has developed three proprietary platforms—AiLNP for nucleic acid delivery system design, AiRNA for mRNA sequence optimization, and AiTEM for small molecule formulation. These platforms simulate and predict nanoscale interactions to enable the rational design of next-generation nanomaterials and therapeutics. METiS is advancing new possibilities in treating cancer, metabolic and autoimmune disorders, neurodegenerative conditions, and more.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends